Published Paper Details:

Biosimilars are officially approved versions of original biopharmaceutical products whose patents have expired. The first generation of biopharmaceutical products, developed using recombinant technologies, was introduced in the 1980s and are now approaching patent expiration. Biologics are produced by cultured cells or whole organisms, which naturally results in more variability compared to chemical synthesis methods As a result, unlike generic pharmaceuticals, it is not possible to create an identical copy of an innovator product. Biosimilars are approved based on the same rigorous standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines. In the coming decades, biosimilar drugs are expected to surpass small molecule pharmaceuticals. The uptake of biosimilars is expected to keep growing as new blockbuster biological drugs continue to enter the pharmaceutical market. This review discusses the current trends and future prospects of biosimilars.